Option chain shows key data for ZEEKR Intelligent Tech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ZEEKR Intelligent Tech.

ZEEKR Intelligent Tech (NYSE:ZK) Stock, Option Chain

ZEEKR Intelligent Tech

ZEEKR Intelligent Technology Holding Ltd is a fast-growing BEV technology company. By developing and offering next-generation premium BEVs and technology-driven solutions, It aspires to lead the automobile industry's electrification, intelligentization and innovation. Since its inception, It has focused on innovation in BEV architecture, hardware, software, and application of new technologies. It is principally engaged in the commercialization and sales of electric vehicles and batteries, and the provision of automotive-related research and development services.

RIVN

XPEV


Electric vehicle sales just capped off 2024 by setting records. This was true in both the United States and China. American car makers General Motors (NYSE:GM) and Ford Motor (NYSE:F) both saw their EV sales spike,

2 Chinese EV Makers Setting Record Sales and Improving Margins

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

ZEEKR Intelligent Technology Holding Ltd

ZKsync - United States Dollar

ZKB GOLD CORP by ZKB Gold ETF

ZKGC NEW ENERGY LTD by ZKGC NEW ENERGY LTD

ZKGC New Energy Ltd

ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares

ZKH Group Ltd

ZK International Group Co., Ltd - Ordinary Share

ZK International Group Co Ltd

ZKSpace

zkSync - United States Dollar

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on actual results for the first six months of fiscal 2025 and the current outlook for the remainder of the fiscal year, the company is updating its guidance to the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">
Fiscal 2025
Guidance Range [1] [2] (as of February 4, 2025)
</td>
<td colspan="1" rowspan="1">Previous Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
<td colspan="1" rowspan="1">Comments</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$590 million to $630 million</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
<td colspan="1" rowspan="1">Increased midpoint $25 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$350 million to $380 million</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
<td colspan="1" rowspan="1">Decreased midpoint $25 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$940 million to $1.01 billion</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
<td colspan="1" rowspan="1">No change to midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$237 million to $253 million</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
<td colspan="1" rowspan="1">No change to midpoint</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Net Income</td>
<td colspan="1" rowspan="1">$119 million to $129 million</td>
<td colspan="1" rowspan="1">Not previously disclosed</td>
<td colspan="1" rowspan="1">New disclosure</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.26 to $1.34</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
<td colspan="1" rowspan="1">Increased midpoint $0.08</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted Weighted Average Shares</td>
<td colspan="1" rowspan="1">94 million to 96 million</td>
<td colspan="1" rowspan="1">Not previously disclosed</td>
<td colspan="1" rowspan="1">New disclosure</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

PINC

Premier Expects FY25 Net Revenue Of $940M-$1.01B (Prior $930M-$1.02B) Vs $990.75M Est, Adj EPS Of $1.26-$1.34 (Prior $1.16-$1.28) Vs $1.29 Est

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $70 price target.

Price Target

Reiteration

Analyst Ratings

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $70 Price Target

General

B2Gold Announces Constructive Preliminary Economic Assessment Results For Antelope Deposit At Otjikoto Mine In Namibia

Consequently, the Company is providing the following 2025 outlook:
<ul>
<li>Agriculture segment net sales(6) down between 13% and 18% year-over-year, including currency translation effects</li>
<li>Agriculture segment adjusted EBIT margin between 8.5% and 9.5%</li>
<li>Construction segment net sales(6) down between 5% and 10% year-over-year, including currency translation effects</li>
<li>Free Cash Flow of Industrial Activities(7) between $200 million and $500 million</li>
<li>Adjusted diluted EPS(7) between $0.65 to $0.75</li>
</ul>

CNH Industrial FY25 Adj. EPS Outlook Of $0.65-$0.75 Vs, $0.87 Estimate

WIIM

UBS shares are trading lower following Q4 financial results.

PLTR

Palantir shares are trading higher following better-than-expected Q4 financial results and strong FY25 guidance. Multiple analysts raised their price targets on the stock.

ARMK

Aramark Continues To Anticipate FY25 Organic Revenue Growth Of 7.5% - 9.5%, Adjusted EPS Growth Of 23% - 28%

Earnings

CNH Industrial Revises Prior Periods To Reflect An Immaterial Correction To Financial Statements

Dividends

Buybacks

REGN

Regeneron Board Authorized Additional $3B Share Repurchase Program And Initiated Quarterly Cash Dividend Of $0.88/Share

Bonds

Markets

LODE

Comstock Subsidiary Receives Approved For $152M Private Activity Bonds From Oklahoma State Treasurer's Office

Full-Year 2025 Financial Outlook
The following table summarizes the company's full-year financial outlook.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sales&#x2A;</td>
<td colspan="1" rowspan="1">$64.1 billion to $65.6 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Gross margin2</td>
<td colspan="1" rowspan="1">Approximately 82.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAPOperating expenses2&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">$25.4 billion to $26.4 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAPOther (income) expense, net2</td>
<td colspan="1" rowspan="1">$300 million to $400 million expense</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAPEffective tax rate2</td>
<td colspan="1" rowspan="1">16.0% to 17.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAPEPS2&#x2A;&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">$8.88 to $9.03</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share count (assuming dilution)</td>
<td colspan="1" rowspan="1">Approximately 2.53 billion</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Large Cap

Health Care

Merck Expects 2025 Sales Of $ $64.1B-$65.6B Versus Consensus Of $67.31B, With Adjusted EPS Of $8.88-$9.03 Versus Consensus Of $9.02

CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.18 by 88.89 percent. This is a 15 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $4.876 billion which beat the analyst consensus estimate of $4.513 billion by 8.04 percent. This is a 28.21 percent decrease over sales of $6.792 billion the same period last year.

Earnings Beats

CNH Industrial Q4 2024 Adj. EPS $0.34 Beats $0.18 Estimate, Sales $4.876B Beat $4.513B Estimate

The Company's new business pipeline across the organization remains significant, including in first-time outsourcing. Aramark is confident in its ability to achieve Net New of 4% to 5% of prior year revenue—with retention levels above 95%—in fiscal 2025 and beyond.&nbsp;

Aramark Continues To Expect Revenue Growth To Accelerate, Particularly In H2 Of The Year, Resuming Double-digit Top-line Growth; Reaffirms Performance Expectations For FY25

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and maintains $1.3 price target.

HC Wainwright & Co. Reiterates Buy on Northern Dynasty Minerals, Maintains $1.3 Price Target

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) reported quarterly earnings of $0.59 per share which missed the analyst consensus estimate of $0.63 by 6.35 percent. This is a 21.33 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $2.095 billion which missed the analyst consensus estimate of $2.161 billion by 3.05 percent. This is a 6.85 percent decrease over sales of $2.249 billion the same period last year.

Earnings Misses

Graphic Packaging Holding Q4 2024 Adj. EPS $0.59 Misses $0.63 Estimate, Sales $2.095B Miss $2.161B Estimate

Regeneron Sees 2025 Non-GAAP Gross Margin On Net Product Sales 87%–88%

Premier Q2 2025 Adj. EPS $0.27 Misses $0.30 Estimate, Sales $240.266M Miss $243.217M Estimate

Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.48 by 6.25 percent. This is a 24.39 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $4.55 billion which missed the analyst consensus estimate of $4.62 billion by 1.41 percent. This is a 3.27 percent increase over sales of $4.41 billion the same period last year.

Aramark Q1 2025 Adj EPS $0.51 Beats $0.48 Estimate, Sales $4.55B Miss $4.62B Estimate

Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.62 by 6.17 percent. This is a 5633.33 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $15.62 billion which beat the analyst consensus estimate of $15.49 billion by 0.84 percent. This is a 6.79 percent increase over sales of $14.63 billion the same period last year.

Merck & Co Q4 2024 Adj EPS $1.72 Beats $1.62 Estimate, Sales $15.62B Beat $15.49B Estimate

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported quarterly earnings of $12.07 per share which beat the analyst consensus estimate of $11.29 by 6.91 percent. This is a 1.77 percent increase over earnings of $11.86 per share from the same period last year. The company reported quarterly sales of $3.790 billion which beat the analyst consensus estimate of $3.751 billion by 1.04 percent. This is a 10.37 percent increase over sales of $3.434 billion the same period last year.

Regeneron Pharmaceuticals Q4 2024 Adj. EPS $12.07 Beats $11.29 Estimate, Sales $3.790B Beat $3.751B Estimate

Press Releases

ZEEKR Announces August 2024 Delivery Update

SunCar Technology Reports 27% Revenue Growth, Including 55% Increase in Auto e-Insurance Business and Over 250% Increase in the Number of Electric Vehicle Insurance Policies in 1H 2024

Comments

ZEEKR Intelligent Tech

ZEEKR Intelligent Tech (ZK) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga